The approval of QUVIVIQâ„¢, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary ...
Marin Cilic has not played an ATP-level event since February but has been handed a wildcard for the Hangzhou Open - taking ...
Marin Cilic could be set to climb a staggering 405 places in the ATP rankings after excelling in his comeback tournament. The ...